Caris Life Sciences, Inc.

Total Valuation

Caris Life Sciences, Inc. carries a market capitalization of 7.09B, placing it among publicly traded companies globally. Its enterprise value stands at 4.69B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Caris Life Sciences, Inc. currently has 282.58M shares outstanding.

Valuation Ratios

Caris Life Sciences, Inc. trades at a trailing price-to-earnings ratio of 47.87. The price-to-sales ratio is 5.09, and the price-to-book ratio stands at 8.51.

Enterprise Valuation

On an enterprise value basis, Caris Life Sciences, Inc. trades at an EV/EBITDA multiple of 26.98 and an EV/FCF ratio of 19.72. The EV/Sales ratio of 4.74 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 30.63 provides insight into valuation relative to core operating earnings.

Financial Position

Caris Life Sciences, Inc. maintains a current ratio of 5.53, meaning it holds 5.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 76.45, indicating elevated leverage, while an interest coverage ratio of 3.71 demonstrates adequate ability to service its debt obligations.

Financial Efficiency

Taxes

Stock Price Statistics

Caris Life Sciences, Inc.'s stock has declined approximately -28.06313% over the past 52 weeks. The 50-day moving average sits at 19.85, while the 200-day moving average is 20.94.

Income Statement

Over the trailing twelve months, Caris Life Sciences, Inc. generated 989.61M in revenue and converted that into 105.14M in net income, yielding earnings per share of 0.36. EBITDA reached 174.03M, while operating income came in at 153.26M.

Balance Sheet

Caris Life Sciences, Inc. holds 793.12M in cash and equivalents against 452.40M in total debt, resulting in a net debt position of -297.76M. Total book value stands at 591.73M, with working capital of 866.39M providing operational flexibility.

Cash Flow

Caris Life Sciences, Inc. produced 168.56M in operating cash flow over the past twelve months. After subtracting -22.53M in capital expenditures, free cash flow totaled 146.03M - equivalent to 0.52 per share.

Margins

Caris Life Sciences, Inc. operates with a gross margin of 69.66, reflecting its pricing power and cost economics. The operating margin of 15.49 and net profit margin of 10.62 provide insight into operational efficiency.

Dividends & Yields

Scores

Caris Life Sciences, Inc. posts an Altman Z-Score of 3.88, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.